ClinicalTrials.gg
CompletedNCT04762680Updated Sep 18, 2025Results posted

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

A Phase 2/3 interventional study of SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1 and SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2 in COVID-19, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 66 sites in 7 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
3,159
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
89th of 1,321
3,159 · median 91
Started
2021
with 503 others
Phase 2/3
70 of 1,859
1 open now
Registered
973rd of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 89th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 70 in phase 2/3, and was the 973rd registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of the study are:

To assess the safety profile of the study vaccines in each study intervention group.

To assess the neutralizing antibody profile after primary series vaccination in SARS-CoV-2-naïve adults.

To demonstrate that a booster dose of monovalent or bivalent SARS-CoV-2 vaccine given to adults previously vaccinated with an authorized/approved COVID-19 vaccine induces an immune response that is non-inferior to the response induced by a twodose priming series with the monovalent vaccine, and superior to that observed immediately before booster.

The secondary objectives of the study are:

To assess the neutralizing and binding antibody profiles after primary series vaccination at pre-defined time points during the study.

To assess the neutralizing and binding antibody responses of booster vaccination.

To describe the occurrences of laboratory-confirmed symptomatic COVID19 after primary series and booster vaccination.

To describe the occurrences of serologically-confirmed SARS-CoV-2 infection after primary series vaccination.

Read the detailed description

The duration of each participant's participation in the study will be approximately:

Original Phase 2 part: 365 days postinjection 2 (ie, 386 days total). Supplemental Cohorts 1 and 2: 365 days post-booster injection (ie, 366 days total).

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Aged 18 years or older on the day of inclusion. - -A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: Is of non-. To be considered of non-childbearing potential, a female mut be for at least 1 year or surgically sterile.

OR Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination (ie, second dose of primary series or booster injection). A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 4 hours before any dose of study intervention. - - form has been signed and dated.

Able to attend all scheduled visits and to comply with all study procedures. SARS-CoV-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of SARS-CoV-2 antibodies (Original Phase 2 Cohort).

For persons living with (HIV), stable HIV infection determined by participant currently on antiretrovirals with > 200/mm3.

Does not intend to receive an authorized/approved COVID-19 vaccine from first vaccination to 3 weeks after the second vaccination despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment.

Supplemental cohorts: for participants originally enrolled in the Phase II cohort of the study, informed consent has to be signed and dated for transitioning to Supplemental Cohort 2.

Supplemental cohorts, Booster arms: received a complete primary vaccination series with an authorized/conditionally approved mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer/BioNTech]) or adenovirus-vectored COVID-19 vaccine (ChAdOx1 nCoV-19 [Oxford University/AstraZeneca] or Ad26.CoV2.S [J\&J/Janssen]), with the last dose administered a minimum of 4 months prior to inclusion but not longer than 10 months prior to inclusion.

Exclusion criteria

Exclusion Criteria:

-Known systemic to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances.

Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures based on Investigator or designee's judgment.

Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator's judgment.

Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on Investigator's judgment.

Unstable acute or chronic illness that in the opinion of the Investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures.

Receipt of solid-organ or bone marrow transplants in the past 180 days. Receipt of anti-cancer chemotherapy in the last 90 days. Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months.

Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A prospective participant should not be included in the trial until the condition has resolved or the febrile event has subsided. Receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention.

Applicable to Original Phase II Cohort, Supplemental Cohort 1 and Cohort 2 Comparator Group: Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV]). Participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study trial period in another clinical study investigating a vaccine, drug, medical device, or medical procedure. Exclusion criterion for the Supplemental Cohort 1 and Cohort 2 comparator group: positive rapid diagnostic test for SARS-CoV-2 antibodies at time of enrollment.

Exclusion criterion for participants in Supplemental Cohort 2 who were primed as participant in the Original Phase II Cohort of the present study: Receipt of authorized/conditionally approved COVID-19 vaccine after enrollment in Original Phase 2 Cohort.

Exclusion criterion for all Booster groups: Documented virologically-confirmed SARS-CoV-2 infection (by NAAT) after first dose of primary immunization.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,159 participants (actual)

Study arms

  • Experimental
    Phase 2 Cohort -SARS-CoV-2 vaccine Formulation 1

    2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22

    Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1

  • Experimental
    Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 2

    2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22

    Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2

  • Experimental
    Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 3

    2 injections of SARS-CoV-2 vaccine Formulation 3 Day 1 and Day 22

    Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3

  • Experimental
    Supplemental Cohort 1 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine

    Participants who were previously vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A

  • Experimental
    Supplemental Cohort 2 - Booster Monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine

    Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03

  • Experimental
    Supplemental Cohort 2 - Booster Bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine

    Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03

  • Experimental
    Supplemental Cohort 2 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine

    Participants who were vaccinated 4 to \< 10 months prior with SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A

  • Active comparator
    Supplemental Comparator for Cohort 1 and 2 Boosters - Monovalent (D614)-AS03 SARS-CoV-2 vaccine

    2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B

  • Experimental
    Cohort 2 - Booster Exploratory 1

    Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1

  • Experimental
    Cohort 2 - Booster Exploratory 2

    Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2

  • Experimental
    Cohort 2 - Booster Exploratory 3

    Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3

  • Experimental
    Cohort 2 - Booster Exploratory 4

    Participants who were vaccinated 4 to \< 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine

    Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4

Interventions

  • BiologicalSARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19

  • BiologicalSARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 Formulation 2

  • BiologicalSARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 Formulation 3

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (D614)-AS03, Dosage A

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (B.1.351)-AS03

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (D614)-AS03, Dosage B

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 1

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 2

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 3

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (B.1.351)-AS03 Alternative Exploratory Formulation 4

  • BiologicalSARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03

    Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection

    Also known as: rSP-COVID19 (D614+B.1.351)-AS03

06

What researchers measure

Primary outcomes

  1. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immediate events were recorded to capture medically relevant unsolicited systemic AEs which occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.

    Time frame: Up to 30 minutes after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)

  2. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Solicited Injection Site Reactions and Systemic Reactions

    A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF, and were considered to be related to the study vaccine administered. An injection site reaction was an AR at and around the injection site of the study vaccine. Systemic AR were all ARs that were not injection site reactions.

    Time frame: Up to 7 days after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)

  3. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Unsolicited Adverse Events

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

    Time frame: Up to 21 days after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)

  4. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)

    An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was 1 of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor could be appropriate. An MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/guardian to seek unplanned medical advice at a physician's office or Emergency Department.

    Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.

  5. Phase 2: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) D614G Strain at Day 1

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Pre-vaccination on Day 1

  6. Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Day 36

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Day 36

  7. Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Day 1 (pre-vaccination) and Day 36

  8. Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36

    Responders were participants who had baseline values below lower limit of quantification (LLOQ) with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point.

    Time frame: Day 36

  9. Phase 3: Cohorts 1 and 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 1

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Pre-vaccination on Day 1

  10. Phase 3: Cohorts 1, 2 and Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Cohorts 1 and 2: 14 days post-vaccination on Day 1, Day 15; Comparator: 14 days post-vaccination on Day 22, Day 36

  11. Phase 3: Comparator: Percentage of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 36

    Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 36

Secondary outcomes

  1. Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Post-vaccination on Days 22, 78, 134, 202, 292, and 387

  2. Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 78, 134, 202, 292, and 387

  3. Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387

    Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay).

    Time frame: Post-vaccination on Days 22, 78, 134, 202, 292, and 387

  4. Phase 2: Geometric Mean Concentration (GMC) of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 78, 134, 202, 292, and 387

    Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-enzyme-linked immunosorbent assay (ELISA) and the results were expressed as geometric mean titers.

    Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387

  5. Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387

    Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387

  6. Phase 2: Number of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387

    Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay.

    Time frame: Post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387

  7. Phase 3: Cohort 1: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 29, 91, 181, and 366

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Post-vaccination on Days 29, 91, 181, and 366

  8. Phase 3: Cohort 1: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, 91, 181, and 366

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, 91, 181, and 366

  9. Phase 3: Cohorts 1, 2 and Comparator: Percentage of Participants With Seroresponse Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination

    Seroresponse was defined as a \>=4-fold rise in serum neutralization titer against SARS-CoV-2 D614G strain and B.1.351 variant (post/pre) at Day 15 or Day 36 relative to Day 0 or Day 22. Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Percentages are rounded off to the tenth decimal place.

    Time frame: Cohorts 1 and 2: 14 days post-vaccination on Day 1 (Day 15); Comparator: 14 days post-vaccination on Day 22 (Day 36)

  10. Phase 3: Cohorts 1 and 2: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 15, 29, 91, 181, and 366

    Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.

    Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 15, 29, 91, 181, and 366

  11. Phase 3: Cohorts 1 and 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 15, 29, 91, 181, and 366

    Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, 91, 181, and 366

  12. Phase 3: Cohort 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 15, 29, and 91

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 15, 29, and 91

  13. Phase 3: Cohort 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, and 91

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, and 91

  14. Phase 3: Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 22, 36, 134, 202, 292, and 387

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

    Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 134, 202, 292, and 387

  15. Phase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 22, 36, 134, 202, 292, and 387

    Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 134, 202, 292, and 387

  16. Phase 3: Comparator: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 134, 202, 292, and 387

    Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.

    Time frame: Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 134, 202, 292, and 387

  17. Phase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387

    Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

    Time frame: Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 134, 202, 292, and 387

  18. Phase 3: Comparator: Percentage of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387

    Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA. Percentages are rounded off to the tenth decimal place.

    Time frame: Post-vaccination on Days 22, 36, 134, 202, 292, and 387

  19. Phase 2: Percentage of Participants With Serologically-Confirmed SARS-CoV-2 Infection

    Blood samples collected from participants were used for serological assessments in the study. Serologically-confirmed SARS-CoV-2 infection was defined as a positive result in a serum sample for antibodies specific to the nucleocapsid of SARS-CoV-2 detected by electrochemiluminescence immunoassay. Percentages are rounded off to the tenth decimal place.

    Time frame: From first dose of study vaccine administration (Day 1) up to 387 days

  20. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Laboratory-Confirmed Symptomatic COVID-19

    Laboratory-confirmed SARS-CoV-2 infection was defined as a positive result for SARS-CoV-2 by nucleic acid amplification test (done by the central laboratory or locally) on at least 1 respiratory sample. Percentages are rounded off to the tenth decimal place.

    Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.

  21. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Symptomatic COVID-19 Episodes Associated With Hospitalization

    Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.

    Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.

  22. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Severe Symptomatic COVID-19

    Severe COVID-19 was defined as COVID-19 with any 1: Any clinical signs of severe illness measured at least on 2 occasions separated by 30 minutes, supplemental oxygen administration for \>1 hour, use of invasive or non-invasive ventilation or Extracorporeal Membrane Oxygenation, clinical diagnosis of respiratory failure, significant acute renal, hepatic, or neurologic dysfunction, shock (defined by systolic blood pressure ˂90 millimeter of mercury (mmHg), or diastolic blood pressure ˂60 mmHg or requiring vasopressors), admission to an intensive care unit, or death. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.

    Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.

  23. Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Death Associated With Symptomatic COVID-19

    Death associated with COVID-19 was defined as death in a participant with COVID-19 who died within 28 days of the first positive specimen date OR died more than 28 days after the first specimen date and COVID-19 was mentioned as an immediate or underlying cause of death on the death certificate. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.

    Time frame: Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.

07

Results

Posted Sep 18, 2025

Participant flow

The Phase 2 of study was conducted at 20 centers between 24 February 2021 and 01 May 2021. The Phase 3 of study was conducted at 110 centers between 29 July 2021 and 06 January 2023. CoV2 preS dTM= Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prefusion Spike delta TM, PBP=Pfizer/BioNTech Primed, MP= Moderna Primed, OUAP= Oxford University/AstraZeneca Primed, JJJP= J\&J/Janssen Primed and PP= Protein Primed.

Phase 2
Participant flow — Phase 2
MilestonePhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)
Started2412392420000000000000000000
Completed1992042040000000000000000000
Not completed4235380000000000000000000
Withdrew: Adverse event0100000000000000000000
Withdrew: Protocol violation5510000000000000000000
Withdrew: Withdrawal by subject2321280000000000000000000
Withdrew: Lost to follow-up14890000000000000000000
Phase 3
Participant flow — Phase 3
MilestonePhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)
Started0003293783781131121081271011011053838132784790000
Completed0003023383371021051001199598943231126713680000
Not completed00027404111788631167671110000
Withdrew: Adverse event0001000000000000030000
Withdrew: Protocol violation00041510000230010100000
Withdrew: Withdrawal by subject00013171283243132146320000
Withdrew: Lost to follow-up0009222424643054611660000
Phase 3 - Exploratory
Participant flow — Phase 3 - Exploratory
MilestonePhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)
Started0000000000000000004899
Completed0000000000000000004798
Not completed0000000000000000000101
Withdrew: Withdrawal by subject0000000000000000000001
Withdrew: Lost to follow-up0000000000000000000100

Outcome measures

SecondaryPhase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387

Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Post-vaccination on Days 22, 78, 134, 202, 292, and 387
Reported as:
Geometric mean · titers
Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387
titersPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Day 2236.0 (29.4 to 44.2)39.6 (32.3 to 48.6)47.3 (37.8 to 59.1)
Day 78467 (361 to 606)558 (438 to 711)569 (458 to 707)
Day 134225 (160 to 318)249 (182 to 340)260 (190 to 358)
Day 202254 (158 to 408)344 (208 to 570)259 (159 to 421)
Day 29212145 (3643 to 40491)2518 (335 to 18928)804 (108 to 6014)
Day 38717837 (9491 to 33522)46305 (24179 to 88677)8353 (1414 to 49336)
SecondaryPhase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387

Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Pre-vaccination on Day 1 and Post-vaccination on Days 22, 78, 134, 202, 292, and 387
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Day 22: >=2-fold rise354453
Day 22: >=4-fold rise283644
Day 78: >=2-fold rise108116113
Day 78: >=4-fold rise105115110
Day 134: >=2-fold rise858782
Day 134: >=4-fold rise758376
Day 202: >=2-fold rise576262
Day 202: >=4-fold rise535760
Day 292: >=2-fold rise101011
Day 292: >=4-fold rise1098
Day 387: >=2-fold rise10911
Day 387: >=4-fold rise10911
SecondaryPhase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387

Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay).

Time frame:
Post-vaccination on Days 22, 78, 134, 202, 292, and 387
Reported as:
Count of participants · Participants
Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Days 22, 78, 134, 202, 292, and 387
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Day 22354453
Day 78108116113
Day 134858782
Day 202576262
Day 292101011
Day 38710911
SecondaryPhase 2: Geometric Mean Concentration (GMC) of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 78, 134, 202, 292, and 387

Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-enzyme-linked immunosorbent assay (ELISA) and the results were expressed as geometric mean titers.

Time frame:
Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387
Reported as:
Geometric mean · titers
Phase 2: Geometric Mean Concentration (GMC) of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 78, 134, 202, 292, and 387
titersPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Day 110.3 (9.54 to 11.1)9.99 (9.52 to 10.5)10.2 (9.77 to 10.7)
Day 22103 (80.6 to 131)149 (119 to 187)228 (182 to 285)
Day 3615533 (13000 to 18560)17176 (14468 to 20390)18003 (15039 to 21550)
Day 786572 (5469 to 7897)7526 (6112 to 9267)7133 (5848 to 8700)
Day 1342750 (2104 to 3594)2977 (2305 to 3846)2696 (2064 to 3521)
Day 2021414 (983 to 2033)1961 (1369 to 2809)1438 (978 to 2113)
Day 29240589 (10633 to 155000)9247 (1625 to 52615)5557 (1183 to 26116)
Day 38761087 (40242 to 92728)58674 (12370 to 278000)16234 (3146 to 83760)
SecondaryPhase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387

Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Day 22: >=2-fold rise141155161
Day 22: >=4-fold rise117136156
Day 36: >=2-fold rise159160165
Day 36: >=4-fold rise158160165
Day 78: >=2-fold rise121124124
Day 78: >=4-fold rise121124124
Day 134: >=2-fold rise101109100
Day 134: >=4-fold rise101109100
Day 202: >=2-fold rise859186
Day 202: >=4-fold rise859185
Day 292: >=2-fold rise111214
Day 292: >=4-fold rise111214
Day 387: >=2-fold rise101013
Day 387: >=4-fold rise101013
SecondaryPhase 2: Number of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387

Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay.

Time frame:
Post-vaccination on Days 22, 36, 78, 134, 202, 292, and 387
Reported as:
Count of participants · Participants
Phase 2: Number of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 78, 134, 202, 292, and 387
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Day 22139154161
Day 36159160165
Day 78121124124
Day 134101109100
Day 202859186
Day 292111214
Day 387101013
SecondaryPhase 3: Cohort 1: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 29, 91, 181, and 366

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Post-vaccination on Days 29, 91, 181, and 366
Reported as:
Geometric mean · titers
Phase 3: Cohort 1: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 29, 91, 181, and 366
titersPhase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)
Day 29: D614G5795 (5222 to 6432)5743 (4668 to 7065)4869 (4113 to 5764)4400 (3566 to 5430)
Day 29: B.1.3512078 (1844 to 2342)1726 (1355 to 2198)1790 (1452 to 2207)1390 (1095 to 1764)
Day 91: D614G4623 (4037 to 5295)4879 (3774 to 6308)2704 (2065 to 3541)2509 (1954 to 3223)
Day 91: B.1.3511522 (1304 to 1776)1254 (920 to 1711)949 (702 to 1281)711 (540 to 936)
Day 181: D614G7502 (6161 to 9135)10068 (6940 to 14605)2658 (1834 to 3852)5649 (3695 to 8635)
Day 181: B.1.3512328 (1827 to 2966)3217 (2073 to 4992)1035 (650 to 1648)1853 (1095 to 3134)
Day 366: D614G10224 (8101 to 12903)10567 (6608 to 16898)2940 (1779 to 4858)6314 (3847 to 10361)
Day 366: B.1.3513419 (2572 to 4545)3349 (1929 to 5812)942 (533 to 1664)2233 (1267 to 3937)
SecondaryPhase 3: Cohort 1: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, 91, 181, and 366

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, 91, 181, and 366
Reported as:
Count of participants · Participants
Phase 3: Cohort 1: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, 91, 181, and 366
ParticipantsPhase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)
D614G; Day 15: >=2-fold rise263869570
D614G; Day 15: >=4-fold rise252708766
D614G; Day 29: >=2-fold rise266919773
D614G; Day 29: >=4-fold rise250798768
D614G; Day 91: >=2-fold rise208746762
D614G; Day 91: >=4-fold rise187575856
D614G; Day 181: >=2-fold rise167505451
D614G; Day 181: >=4-fold rise149444241
D614G; Day 366: >=2-fold rise141383331
D614G; Day 366: >=4-fold rise129342831
B.1.351; Day 15: >=2-fold rise2587610978
B.1.351; Day 15: >=4-fold rise2466710376
B.1.351; Day 29: >=2-fold rise2617910983
B.1.351; Day 29: >=4-fold rise2457010380
B.1.351; Day 91: >=2-fold rise203647568
B.1.351; Day 91: >=4-fold rise189546766
B.1.351; Day 181: >=2-fold rise162385954
B.1.351; Day 181: >=4-fold rise145385146
B.1.351; Day 366: >=2-fold rise137323634
B.1.351; Day 366: >=4-fold rise127303430
SecondaryPhase 3: Cohorts 1, 2 and Comparator: Percentage of Participants With Seroresponse Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination

Seroresponse was defined as a \>=4-fold rise in serum neutralization titer against SARS-CoV-2 D614G strain and B.1.351 variant (post/pre) at Day 15 or Day 36 relative to Day 0 or Day 22. Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Percentages are rounded off to the tenth decimal place.

Time frame:
Cohorts 1 and 2: 14 days post-vaccination on Day 1 (Day 15); Comparator: 14 days post-vaccination on Day 22 (Day 36)
Reported as:
Number · percentage of participants
Phase 3: Cohorts 1, 2 and Comparator: Percentage of Participants With Seroresponse Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination
percentage of participantsPhase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
D614G90.6 (86.6 to 93.8)73.7 (68.4 to 78.4)75.6 (70.5 to 80.2)71.4 (61.4 to 80.1)72.8 (62.6 to 81.6)63.7 (53.0 to 73.6)86.1 (77.8 to 92.2)89.7 (81.3 to 95.2)89.8 (81.5 to 95.2)88.0 (78.4 to 94.4)58.1 (39.1 to 75.5)78.8 (61.1 to 91.0)84.8 (76.2 to 91.3)90.6 (80.7 to 96.5)99.0 (97.1 to 99.8)
B.1.35192.5 (88.6 to 95.3)83.3 (78.6 to 87.3)82.9 (78.1 to 87.0)84.8 (75.0 to 91.9)83.3 (73.6 to 90.6)80.0 (69.9 to 87.9)90.4 (83.4 to 95.1)95.4 (88.6 to 98.7)96.7 (90.7 to 99.3)93.8 (86.2 to 98.0)75.9 (56.5 to 89.7)77.4 (58.9 to 90.4)85.9 (77.4 to 92.0)90.6 (80.7 to 96.5)86.6 (82.1 to 90.3)
SecondaryPhase 3: Cohorts 1 and 2: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 15, 29, 91, 181, and 366

Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.

Time frame:
Pre-vaccination on Day 1 and post-vaccination on Days 15, 29, 91, 181, and 366
Reported as:
Geometric mean · titers
Phase 3: Cohorts 1 and 2: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 15, 29, 91, 181, and 366
titersPhase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)
Day 11888 (1687 to 2114)3032 (2621 to 3507)2580 (2228 to 2987)3236 (2729 to 3839)3285 (2534 to 4259)3505 (2747 to 4471)993 (781 to 1262)564 (427 to 747)537 (420 to 687)608 (457 to 809)2290 (1068 to 4908)996 (491 to 2021)1357 (1004 to 1834)969 (688 to 1365)
Day 1526710 (24337 to 29314)36428 (33227 to 39938)30892 (27925 to 34174)27390 (23220 to 32309)43611 (35852 to 53049)34704 (29398 to 40968)21654 (18927 to 24775)23775 (19137 to 29537)28783 (24417 to 33930)21758 (18254 to 25935)31067 (24221 to 39849)34534 (26146 to 45614)65824 (57576 to 75254)77057 (61772 to 96125)
Day 2920212 (18487 to 22097)33416 (30407 to 36723)27083 (24480 to 29964)23079 (19417 to 27431)48428 (39336 to 59623)41018 (34290 to 49065)13305 (11657 to 15186)16401 (13253 to 20296)17729 (14944 to 21034)14014 (11798 to 16647)29315 (22236 to 38647)24388 (17369 to 34243)60707 (52764 to 69845)65974 (53800 to 80902)
Day 9118845 (16780 to 21165)29384 (25972 to 33244)23908 (20860 to 27402)20758 (16506 to 26107)37791 (29062 to 49140)35363 (28656 to 43639)9792 (8093 to 11849)10365 (8105 to 13255)13189 (10078 to 17261)9032 (7387 to 11043)18463 (13497 to 25255)16236 (9684 to 27219)41282 (34967 to 48736)40566 (32032 to 51373)
Day 18120073 (17076 to 23596)20450 (18029 to 23195)18628 (16117 to 21530)25701 (17854 to 36998)25615 (20346 to 32248)24500 (19714 to 30448)7281 (5366 to 9880)8665 (6100 to 12311)10649 (7312 to 15510)12342 (8420 to 18092)11275 (7727 to 16451)19231 (12448 to 29712)21387 (17825 to 25661)20803 (16151 to 26794)
Day 36641232 (28233 to 60218)19545 (17037 to 22422)19989 (17351 to 23028)32368 (16026 to 65374)25800 (20031 to 33232)19848 (15543 to 25345)—10382 (6531 to 16505)10937 (6565 to 18220)14545 (4542 to 46582)12176 (8897 to 16664)12002 (8266 to 17425)32168 (25602 to 40417)33194 (24774 to 44476)
SecondaryPhase 3: Cohorts 1 and 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 15, 29, 91, 181, and 366

Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, 91, 181, and 366
Reported as:
Count of participants · Participants
Phase 3: Cohorts 1 and 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 15, 29, 91, 181, and 366
ParticipantsPhase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)
Day 15: >=2-fold rise287276292948487114929288242910869
Day 15: >=4-fold rise265234265727369106859084192810367
Day 29: >=2-fold rise285278285938787111929091242711569
Day 29: >=4-fold rise25324325471757496858684192710966
Day 91: >=2-fold rise22721021773707682615979172310565
Day 91: >=4-fold rise1971831846062586957567214229862
Day 181: >=2-fold rise1751891934363595953495614209862
Day 181: >=4-fold rise1461601673855484545405111178959
Day 366: >=2-fold rise27174184156249—2627912178353
Day 366: >=4-fold rise26147165135637—2323711147752
SecondaryPhase 3: Cohort 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 15, 29, and 91

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Pre-vaccination on Day 1 and post-vaccination on Days 15, 29, and 91
Reported as:
Geometric mean · titers
Phase 3: Cohort 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 15, 29, and 91
titersPhase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)
Day 1: D614G678 (558 to 824)579 (478 to 701)1107 (816 to 1503)1347 (977 to 1858)137 (98.0 to 193)134 (95.7 to 186)1188 (567 to 2490)447 (217 to 921)274 (182 to 413)159 (97.4 to 260)
Day 1: B.1.351176 (142 to 217)149 (120 to 184)258 (182 to 364)296 (207 to 424)43.3 (32.0 to 58.5)36.8 (28.8 to 47.1)345 (167 to 714)122 (55.3 to 268)97.7 (68.0 to 140)70.3 (47.9 to 103)
Day 15: D614G9995 (8976 to 11129)8430 (7572 to 9386)14240 (11257 to 18013)12522 (10368 to 15123)5536 (4436 to 6910)5855 (4669 to 7344)11005 (7533 to 16078)11624 (8086 to 16710)22457 (19123 to 26374)25002 (18441 to 33897)
Day 15: B.1.3517021 (6262 to 7873)4900 (4370 to 5494)9449 (7376 to 12104)6581 (5340 to 8111)4610 (3689 to 5760)3099 (2386 to 4026)6872 (4482 to 10537)5057 (3416 to 7488)7452 (6212 to 8939)13300 (9817 to 18018)
Day 29: D614G14065 (12399 to 15954)10885 (9664 to 12261)16286 (12808 to 20710)16874 (13763 to 20688)6320 (4941 to 8083)6370 (5014 to 8093)9711 (6526 to 14450)9521 (6555 to 13828)16032 (13535 to 18989)16425 (12103 to 22291)
Day 29: B.1.3518947 (7845 to 10203)6045 (5307 to 6886)10264 (7924 to 13296)8139 (6470 to 10239)4736 (3680 to 6096)3103 (2340 to 4115)6028 (3889 to 9342)4007 (2553 to 6290)7185 (5841 to 8838)12712 (9376 to 17234)
Day 91: D614G11037 (9530 to 12782)8523 (7284 to 9973)13701 (10206 to 18392)12424 (9586 to 16103)3620 (2680 to 4891)3981 (2812 to 5637)5797 (3725 to 9024)5880 (3125 to 11064)14498 (11931 to 17618)13641 (9766 to 19055)
Day 91: B.1.3516557 (5617 to 7654)4359 (3673 to 5172)8141 (5982 to 11080)5474 (4176 to 7175)2456 (1792 to 3364)2029 (1376 to 2993)3374 (2161 to 5269)2405 (1093 to 5295)6455 (5117 to 8143)8990 (6284 to 12861)
SecondaryPhase 3: Cohort 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, and 91

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Pre-vaccination on Day 1 and Post-vaccination on Days 15, 29, and 91
Reported as:
Count of participants · Participants
Phase 3: Cohort 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 15, 29, and 91
ParticipantsPhase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)
D614G; Day 15: >=2-fold rise2672697977858426308660
D614G; Day 15: >=4-fold rise2322426758787918268458
D614G; Day 29: >=2-fold rise2722838376848322288958
D614G; Day 29: >=4-fold rise2402517467808015238556
D614G; Day 91: >=2-fold rise1992086970575116208157
D614G; Day 91: >=4-fold rise1751875754554812167853
B.1.351; Day 15: >=2-fold rise2752697779858828288862
B.1.351; Day 15: >=4-fold rise2492477068838822248558
B.1.351; Day 29: >=2-fold rise2782778179868728269562
B.1.351; Day 29: >=4-fold rise2582617570848720259258
B.1.351; Day 91: >=2-fold rise2122076968565622218758
B.1.351; Day 91: >=4-fold rise1951976260565316178055
SecondaryPhase 3: Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 22, 36, 134, 202, 292, and 387

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 134, 202, 292, and 387
Reported as:
Geometric mean · titers
Phase 3: Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 1, 22, 36, 134, 202, 292, and 387
titersPhase 3: Comparator: CoV2 preS dTM-AS03 (D614)
D614G: Day 120.3 (19.7 to 21.0)
D614G: Day 2253.3 (44.6 to 63.8)
D614G: Day 363658 (3123 to 4286)
D614G: Day 1341050 (743 to 1486)
D614G: Day 2021685 (1142 to 2487)
D614G: Day 2921943 (1294 to 2918)
D614G: Day 3871973 (1344 to 2897)
B.1.351: Day 120.3 (19.7 to 20.8)
B.1.351: Day 2229.4 (25.7 to 33.5)
B.1.351: Day 36413 (346 to 493)
B.1.351: Day 134496 (330 to 745)
B.1.351: Day 202671 (441 to 1022)
B.1.351: Day 292867 (560 to 1342)
B.1.351: Day 3871033 (686 to 1555)
SecondaryPhase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 22, 36, 134, 202, 292, and 387

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 134, 202, 292, and 387
Reported as:
Count of participants · Participants
Phase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Days 22, 36, 134, 202, 292, and 387
ParticipantsPhase 3: Comparator: CoV2 preS dTM-AS03 (D614)
D614G; Day 22: >=2-fold rise99
D614G; Day 22: >=4-fold rise88
D614G; Day 36: >=2-fold rise299
D614G; Day 36: >=4-fold rise298
D614G; Day 134: >=2-fold rise134
D614G; Day 134: >=4-fold rise131
D614G; Day 202: >=2-fold rise120
D614G; Day 202: >=4-fold rise119
D614G; Day 292: >=2-fold rise108
D614G; Day 292: >=4-fold rise105
D614G; Day 387: >=2-fold rise105
D614G; Day 387: >=4-fold rise101
B.1.351; Day 22: >=2-fold rise39
B.1.351; Day 22: >=4-fold rise32
B.1.351; Day 36: >=2-fold rise264
B.1.351; Day 36: >=4-fold rise251
B.1.351; Day 134: >=2-fold rise99
B.1.351; Day 134: >=4-fold rise89
B.1.351; Day 202: >=2-fold rise100
B.1.351; Day 202: >=4-fold rise97
B.1.351; Day 292: >=2-fold rise98
B.1.351; Day 292: >=4-fold rise91
B.1.351; Day 387: >=2-fold rise96
B.1.351; Day 387: >=4-fold rise94
SecondaryPhase 3: Comparator: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 134, 202, 292, and 387

Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA and the results were expressed as geometric mean titers.

Time frame:
Pre-vaccination on Day 1 and post-vaccination on Days 22, 36, 134, 202, 292, and 387
Reported as:
Geometric mean · titers
Phase 3: Comparator: Geometric Mean Concentration of Binding Antibodies Against SARS-CoV-2 D614G Strain at Days 1, 22, 36, 134, 202, 292, and 387
titersPhase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Day 110.7 (9.91 to 11.6)
Day 22212 (183 to 246)
Day 3624278 (21681 to 27185)
Day 1346593 (4952 to 8779)
Day 2026667 (4833 to 9197)
Day 2926868 (4919 to 9587)
Day 3877112 (5216 to 9697)
SecondaryPhase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387

Binding antibodies concentration against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA assay. Participants with binding antibodies concentration \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Pre-vaccination on Day 1 and Post-vaccination on Days 22, 36, 134, 202, 292, and 387
Reported as:
Count of participants · Participants
Phase 3: Comparator: Number of Participants With >=2-Fold and >=4-Fold Rise in Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387
ParticipantsPhase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Day 22: >=2-fold rise312
Day 22: >=4-fold rise290
Day 36: >=2-fold rise302
Day 36: >=4-fold rise302
Day 134: >=2-fold rise149
Day 134: >=4-fold rise148
Day 202: >=2-fold rise133
Day 202: >=4-fold rise133
Day 292: >=2-fold rise123
Day 292: >=4-fold rise123
Day 387: >=2-fold rise117
Day 387: >=4-fold rise117
SecondaryPhase 3: Comparator: Percentage of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387

Responders were participants who had baseline values below LLOQ with detectable antibody concentration above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Binding antibodies activity against SARS-CoV-2 D614G strain was measured with Nexelis GCN4 S-ELISA. Percentages are rounded off to the tenth decimal place.

Time frame:
Post-vaccination on Days 22, 36, 134, 202, 292, and 387
Reported as:
Number · percentage of participants
Phase 3: Comparator: Percentage of Responders as Determined by Binding Antibody Concentration Against SARS-CoV-2 D614G Strain at Days 22, 36, 134, 202, 292, and 387
percentage of participantsPhase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Day 2294.3 (91.2 to 96.5)
Day 3699.7 (98.3 to 100)
Day 13498.7 (95.5 to 99.8)
Day 20299.3 (96.1 to 100)
Day 29299.3 (95.9 to 100)
Day 38799.2 (95.7 to 100)
SecondaryPhase 2: Percentage of Participants With Serologically-Confirmed SARS-CoV-2 Infection

Blood samples collected from participants were used for serological assessments in the study. Serologically-confirmed SARS-CoV-2 infection was defined as a positive result in a serum sample for antibodies specific to the nucleocapsid of SARS-CoV-2 detected by electrochemiluminescence immunoassay. Percentages are rounded off to the tenth decimal place.

Time frame:
From first dose of study vaccine administration (Day 1) up to 387 days
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Serologically-Confirmed SARS-CoV-2 Infection
percentage of participantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Phase 2: Percentage of Participants With Serologically-Confirmed SARS-CoV-2 Infection12.1 (8.2 to 16.9)10.8 (7.2 to 15.5)14.1 (10.0 to 19.2)
SecondaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Laboratory-Confirmed Symptomatic COVID-19

Laboratory-confirmed SARS-CoV-2 infection was defined as a positive result for SARS-CoV-2 by nucleic acid amplification test (done by the central laboratory or locally) on at least 1 respiratory sample. Percentages are rounded off to the tenth decimal place.

Time frame:
Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Reported as:
Number · percentage of participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Laboratory-Confirmed Symptomatic COVID-19
percentage of participantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Laboratory-Confirmed Symptomatic COVID-193.3 (1.4 to 6.5)1.7 (0.5 to 4.2)5.4 (2.9 to 9.0)14.0 (10.5 to 18.3)20.9 (16.9 to 25.4)23.5 (19.3 to 28.1)12.4 (6.9 to 19.9)10.8 (5.7 to 18.1)10.2 (5.2 to 17.5)24.4 (17.2 to 32.8)25.0 (16.9 to 34.7)29.0 (20.4 to 38.9)9.7 (4.8 to 17.1)0 (0 to 9.3)18.4 (7.7 to 34.3)18.9 (12.6 to 26.7)19.2 (11.2 to 29.7)8.2 (5.9 to 11.1)
SecondaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Symptomatic COVID-19 Episodes Associated With Hospitalization

Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.

Time frame:
Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Reported as:
Number · percentage of participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Symptomatic COVID-19 Episodes Associated With Hospitalization
percentage of participantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Symptomatic COVID-19 Episodes Associated With Hospitalization0 (0 to 1.5)0 (0 to 1.5)0 (0 to 1.5)0 (0 to 1.1)0 (0 to 1.0)0.3 (0 to 1.5)0 (0 to 3.2)0 (0 to 3.3)0 (0 to 3.4)0.8 (0 to 4.3)0 (0 to 3.6)0 (0 to 3.6)0 (0 to 3.5)0 (0 to 9.3)0 (0 to 9.3)0 (0 to 2.8)0 (0 to 4.6)0 (0 to 0.8)
SecondaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Severe Symptomatic COVID-19

Severe COVID-19 was defined as COVID-19 with any 1: Any clinical signs of severe illness measured at least on 2 occasions separated by 30 minutes, supplemental oxygen administration for \>1 hour, use of invasive or non-invasive ventilation or Extracorporeal Membrane Oxygenation, clinical diagnosis of respiratory failure, significant acute renal, hepatic, or neurologic dysfunction, shock (defined by systolic blood pressure ˂90 millimeter of mercury (mmHg), or diastolic blood pressure ˂60 mmHg or requiring vasopressors), admission to an intensive care unit, or death. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.

Time frame:
Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Reported as:
Number · percentage of participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Severe Symptomatic COVID-19
percentage of participantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Severe Symptomatic COVID-190 (0 to 1.5)0 (0 to 1.5)0 (0 to 1.5)0 (0 to 1.1)0 (0 to 1.0)0.3 (0 to 1.5)0 (0 to 3.2)0 (0 to 3.3)0 (0 to 3.4)0 (0 to 2.9)0 (0 to 3.6)0 (0 to 3.6)0 (0 to 3.5)0 (0 to 9.3)0 (0 to 9.3)0.8 (0 to 4.1)0 (0 to 4.6)0 (0 to 0.8)
SecondaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Death Associated With Symptomatic COVID-19

Death associated with COVID-19 was defined as death in a participant with COVID-19 who died within 28 days of the first positive specimen date OR died more than 28 days after the first specimen date and COVID-19 was mentioned as an immediate or underlying cause of death on the death certificate. Symptomatic COVID-19 was defined as laboratory-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness. Percentages are rounded off to the tenth decimal place.

Time frame:
Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Reported as:
Number · percentage of participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Death Associated With Symptomatic COVID-19
percentage of participantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Percentage of Participants With Death Associated With Symptomatic COVID-190 (0 to 1.5)0 (0 to 1.5)0 (0 to 1.5)0 (0 to 1.1)0 (0 to 1.0)0 (0 to 1.0)0 (0 to 3.2)0 (0 to 3.3)0 (0 to 3.4)0 (0 to 2.9)0 (0 to 3.6)0 (0 to 3.6)0 (0 to 3.5)0 (0 to 9.3)0 (0 to 9.3)0 (0 to 2.8)0 (0 to 4.6)0 (0 to 0.8)
PrimaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immediate events were recorded to capture medically relevant unsolicited systemic AEs which occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination.

Time frame:
Up to 30 minutes after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)
Reported as:
Count of participants · Participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs)
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs)211000000000000009
PrimaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Solicited Injection Site Reactions and Systemic Reactions

A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF, and were considered to be related to the study vaccine administered. An injection site reaction was an AR at and around the injection site of the study vaccine. Systemic AR were all ARs that were not injection site reactions.

Time frame:
Up to 7 days after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)
Reported as:
Count of participants · Participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Injection site reaction20119620026230030390827410487878119199846375
Systemic reaction1911911851982382426767657561756214178836359
PrimaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Unsolicited Adverse Events

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

Time frame:
Up to 21 days after each vaccination (Phase 2: Postdose on Days 1 and 22; Phase 3: Between 4 to 10 months after priming vaccine)
Reported as:
Count of participants · Participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Unsolicited Adverse Events
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Unsolicited Adverse Events888191761069629182234273516772511199
PrimaryPhase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)

An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was 1 of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor could be appropriate. An MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/guardian to seek unplanned medical advice at a physician's office or Emergency Department.

Time frame:
Phase 2 and Phase 3 Comparator: From first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: From first dose of study vaccine administration (Day 1) up to 366 days.
Reported as:
Count of participants · Participants
Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs)
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
SAE26489113143401233314
AESI000201100001000011
MAAE4248598010611728251931242919774232110
PrimaryPhase 2: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) D614G Strain at Day 1

Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Pre-vaccination on Day 1
Reported as:
Geometric mean · titers
Phase 2: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) D614G Strain at Day 1
titersPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Phase 2: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) D614G Strain at Day 120.0 (NA to NA)20.0 (NA to NA)20.0 (NA to NA)
PrimaryPhase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Day 36

Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Day 36
Reported as:
Geometric mean · titers
Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Day 36
titersPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Phase 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain at Day 362132 (1690 to 2688)2376 (1873 to 3015)2903 (2289 to 3683)
PrimaryPhase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36

Neutralizing antibodies activity against SARS-CoV-2 D614G strain was measured with serum neutralization assay (monogram assay). Participants with neutralization antibody titers \>=2-fold and \>=4-fold increase from baseline (pre-vaccination) were analyzed.

Time frame:
Day 1 (pre-vaccination) and Day 36
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
>=2-fold rise155156158
>=4-fold rise154154157
PrimaryPhase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36

Responders were participants who had baseline values below lower limit of quantification (LLOQ) with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point.

Time frame:
Day 36
Reported as:
Count of participants · Participants
Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36
ParticipantsPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3
Phase 2: Number of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain at Day 36155156158
PrimaryPhase 3: Cohorts 1 and 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 1

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Pre-vaccination on Day 1
Reported as:
Geometric mean · titers
Phase 3: Cohorts 1 and 2: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 1
titersPhase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)
D614G320 (275 to 373)678 (558 to 824)579 (478 to 701)668 (537 to 830)1107 (816 to 1503)1347 (977 to 1858)265 (190 to 369)137 (98.0 to 193)134 (95.7 to 186)222 (155 to 318)1188 (567 to 2490)447 (217 to 921)274 (182 to 413)159 (97.4 to 260)
B.1.35170.1 (60.3 to 81.4)176 (142 to 217)149 (120 to 184)122 (95.4 to 157)258 (182 to 364)296 (207 to 424)54.1 (41.4 to 70.7)43.3 (32.0 to 58.5)36.8 (28.8 to 47.1)42.6 (32.5 to 55.7)345 (167 to 714)122 (55.3 to 268)97.7 (68.0 to 140)70.3 (47.9 to 103)
PrimaryPhase 3: Cohorts 1, 2 and Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination

Neutralizing antibodies activity against SARS-CoV-2 D614G strain and B.1.351 variant was measured with the neutralization assay (monogram assay) and the results were expressed as geometric mean titers.

Time frame:
Cohorts 1 and 2: 14 days post-vaccination on Day 1, Day 15; Comparator: 14 days post-vaccination on Day 22, Day 36
Reported as:
Geometric mean · titers
Phase 3: Cohorts 1, 2 and Comparator: Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 D614G Strain and B.1.351 Variant at 14 Days Post-Vaccination
titersPhase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)
D614G6964 (6268 to 7737)9995 (8976 to 11129)8430 (7572 to 9386)6347 (5207 to 7736)14240 (11257 to 18013)12522 (10368 to 15123)6257 (5313 to 7369)5536 (4436 to 6910)5855 (4669 to 7344)6875 (5587 to 8460)11005 (7533 to 16078)11624 (8086 to 16710)22457 (19123 to 26374)25002 (18441 to 33897)3611 (3086 to 4224)
B.1.3512610 (2316 to 2942)7021 (6262 to 7873)4900 (4370 to 5494)2222 (1754 to 2814)9449 (7376 to 12104)6581 (5340 to 8111)2062 (1708 to 2489)4610 (3689 to 5760)3099 (2386 to 4026)2054 (1642 to 2568)6872 (4482 to 10537)5057 (3416 to 7488)7452 (6212 to 8939)13300 (9817 to 18018)413 (346 to 493)
PrimaryPhase 3: Comparator: Percentage of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 36

Responders were participants who had baseline values below LLOQ with detectable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody titers at each pre-defined post-vaccination time point. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 36
Reported as:
Number · percentage of participants
Phase 3: Comparator: Percentage of Responders as Determined by Neutralizing Antibody Titers Against SARS-CoV-2 D614G Strain and B.1.351 Variant at Day 36
percentage of participantsPhase 3: Comparator: CoV2 preS dTM-AS03 (D614)
D614G99.3 (97.6 to 99.9)
B.1.35191.0 (87.1 to 94.1)

Adverse events

Collected over Phase 2 and Phase 3 Comparator: AEs data was collected from first dose of study vaccine administration (Day 1) up to 387 days. Phase 3 Cohorts 1 and 2: AEs data was collected from first dose of study vaccine administration (Day 1) up to 366 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 10/240 (0%)2/240 (0.8%)217/240 (90.4%)
Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 20/240 (0%)6/240 (2.5%)215/240 (89.6%)
Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 30/241 (0%)4/241 (1.7%)219/241 (90.9%)
Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)0/328 (0%)8/328 (2.4%)281/328 (85.7%)
Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)0/378 (0%)9/378 (2.4%)328/378 (86.8%)
Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)0/375 (0%)11/375 (2.9%)331/375 (88.3%)
Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)0/113 (0%)3/113 (2.7%)97/113 (85.8%)
Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)0/111 (0%)1/111 (0.9%)88/111 (79.3%)
Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)0/108 (0%)4/108 (3.7%)83/108 (76.9%)
Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)0/127 (0%)3/127 (2.4%)115/127 (90.6%)
Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)0/100 (0%)4/100 (4%)92/100 (92%)
Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)0/100 (0%)0/100 (0%)97/100 (97%)
Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)0/103 (0%)1/103 (1%)89/103 (86.4%)
Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)0/38 (0%)2/38 (5.3%)21/38 (55.3%)
Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)0/38 (0%)3/38 (7.9%)24/38 (63.2%)
Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)0/132 (0%)3/132 (2.3%)112/132 (84.8%)
Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)0/78 (0%)3/78 (3.8%)59/78 (75.6%)
Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)1/473 (0.2%)14/473 (3%)421/473 (89%)
Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)0/4 (0%)2/4 (50%)4/4 (100%)
Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)0/8 (0%)0/8 (0%)7/8 (87.5%)
Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)0/9 (0%)1/9 (11.1%)8/9 (88.9%)
Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)0/9 (0%)1/9 (11.1%)6/9 (66.7%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)
Anal AbscessInfections and infestations0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1030/380/380/1320/780/4731/40/80/90/9
CholecystitisHepatobiliary disorders0/2400/2400/2410/3280/3781/3750/1130/1110/1080/1270/1000/1001/1030/380/380/1320/780/4731/40/80/90/9
Motor Neurone DiseaseNervous system disorders0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1030/380/380/1320/780/4730/40/80/91/9
AbscessInfections and infestations0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1030/380/380/1320/780/4730/40/81/90/9
Periumbilical AbscessInfections and infestations0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1030/380/380/1320/780/4730/40/81/90/9
Angina PectorisCardiac disorders0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1030/381/380/1320/780/4730/40/80/90/9
Alcoholic SeizureNervous system disorders0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1031/380/380/1320/780/4730/40/80/90/9
Cerebrovascular AccidentNervous system disorders0/2401/2400/2410/3281/3780/3750/1130/1110/1080/1270/1000/1000/1030/381/380/1320/780/4730/40/80/90/9
Diabetes MellitusMetabolism and nutrition disorders0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1030/381/380/1320/780/4730/40/80/90/9
Ovarian AbscessInfections and infestations0/2400/2400/2410/3280/3780/3750/1130/1110/1080/1270/1000/1000/1031/380/380/1320/780/4730/40/80/90/9
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPhase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)
Injection Site PainGeneral disorders199/240194/240200/241259/328297/378301/37589/11381/11175/108100/12786/10085/10080/10318/3819/3896/13246/78372/4734/45/87/93/9
HeadacheNervous system disorders141/240134/240134/241130/328167/378165/37547/11350/11139/10845/12748/10055/10037/10310/3810/3851/13220/78278/4732/43/86/93/9
MalaiseGeneral disorders138/240142/240146/241101/328122/378122/37542/11339/11133/10840/12735/10043/10031/1038/387/3861/13225/78241/4731/43/82/93/9
MyalgiaMusculoskeletal and connective tissue disorders143/240135/240123/241123/328145/378153/37541/11348/11143/10840/12736/10054/10033/1039/3811/3861/13227/78275/4732/42/84/94/9
ArthralgiaMusculoskeletal and connective tissue disorders107/240102/240104/24191/328110/378114/37531/11339/11131/10822/12730/10035/10024/1036/387/3842/13218/78228/4730/41/81/91/9
ChillsGeneral disorders97/24093/24077/24150/32874/37877/37516/11323/11123/10823/12723/10031/10010/1035/385/3838/13215/78160/4730/41/81/91/9
Biliary ColicHepatobiliary disorders0/2400/2400/2410/3280/3781/3750/1130/1110/1080/1270/1000/1000/1030/380/380/1320/780/4731/40/80/90/9
Injection Site SwellingGeneral disorders40/24039/24037/24132/32837/37825/37510/1137/1114/10824/1278/1005/1006/1030/383/3811/1323/7872/4730/41/80/90/9
Injection Site ErythemaGeneral disorders28/24041/24026/24132/32823/37819/3758/1137/1114/10822/1278/1009/1005/1031/383/389/1322/7877/4730/40/80/90/9
Covid-19Infections and infestations5/2403/2407/24116/32834/37837/3756/1134/1119/1082/1279/1006/1005/1030/381/3820/13213/7821/4730/40/81/91/9

Baseline characteristics

All Randomized set included all participants with a randomized group allocated by interactive response technology. Participants from the Original Cohort were included in the Booster Cohorts because these assessed separate objectives. To be eligible, participants in the Booster Cohorts were required to have received a primary series, as administered in the Original Cohort.

Age, Categorical
Age, Categorical(Participants)Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)Total
Phase 2 — <=18 years01000000000000000000001
Phase 2 — Between 18 and 65 years1951961960000000000000000000587
Phase 2 — >=65 years4642460000000000000000000134
Phase 3 — <=18 years000042001000100009000017
Phase 3 — Between 18 and 65 years000266357353889794958687983536924046700002291
Phase 3 — >=65 years000631723251513321514632403830000309
Phase 3 - Exploratory — <=18 years00000000000000000000000
Phase 3 - Exploratory — Between 18 and 65 years000000000000000000479828
Phase 3 - Exploratory — >=65 years00000000000000000001012
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)Total
Phase 2 — Female1231141220000000000000000000359
Phase 2 — Male1181251200000000000000000000363
Phase 3 — Female000181208199686064594248631920643821500001348
Phase 3 — Male000148170179455244685953421918684026400001269
Phase 3 - Exploratory — Female000000000000000000338620
Phase 3 - Exploratory — Male000000000000000000151310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 1Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 2Phase 2: CoV2 preS dTM-AS03 (D614) Formulation 3Phase 3: Cohort 1: PBP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: PBP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: MP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: MP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: OUAP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: OUAP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 1: JJJP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Cohort 2: JJJP - CoV2 preS dTM-AS03 (D614 + B.1.351)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (D614)Phase 3: Cohort 2: PP - CoV2 preS dTM-AS03 (B.1.351)Phase 3: Comparator: CoV2 preS dTM-AS03 (D614)Phase 3: Exploratory 1: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 2: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 3: PBP - CoV2 preS dTM (B.1.351)Phase 3: Exploratory 4: PBP - CoV2 preS dTM (B.1.351)Total
Phase 2 — American Indian or Alaska Native2224205562620001422014150000148
Phase 2 — Asian131010191213713114702222180000136
Phase 2 — Black or African American142320155461316322325161072520000337
Phase 2 — Multiple524166131001000018000039
Phase 2 — Native Hawaiian or Other Pacific Islander212021000000010001000010
Phase 2 — White15614915625224724010079611049287991521803737200002347
Phase 2 — Missing293030000000000000000000089
Phase 2 — Not Reported00033444901610120020034789179
Phase 2 — Unknown000482063012001232210011084
Phase 3 — American Indian or Alaska Native000556262000142201415000082
Phase 3 — Asian000191213713114702222180000103
Phase 3 — Black or African American000155461316322325161072520000280
Phase 3 — Multiple000166131001000018000028
Phase 3 — Native Hawaiian or Other Pacific Islander00002100000001000100005
Phase 3 — White00025224724010079611049287991521803737200001886
Phase 3 — Missing00000000000000000000000
Phase 3 — Not Reported00033444901610120020030000151
Phase 3 — Unknown000482063012001232210000082
Phase 3 - Exploratory — American Indian or Alaska Native00000000000000000000000
Phase 3 - Exploratory — Asian00000000000000000000000
Phase 3 - Exploratory — Black or African American00000000000000000000000
Phase 3 - Exploratory — Multiple00000000000000000000000
Phase 3 - Exploratory — Native Hawaiian or Other Pacific Islander00000000000000000000000
Phase 3 - Exploratory — White00000000000000000000000
Phase 3 - Exploratory — Missing00000000000000000000000
Phase 3 - Exploratory — Not Reported000000000000000000478928
Phase 3 - Exploratory — Unknown00000000000000000001102
08

Study locations

66 sites
  • Synexus - Clinical Research Advantage, Inc. Site Number : 8400270
    Birmingham, Alabama 35205, United States
  • Synexus Chandler Site Number : 8400251
    Chandler, Arizona 85225, United States
  • Synexus - Glendale. Site Number : 8400271
    Glendale, Arizona 85306, United States
  • Baptist Health Center for Clinical Research Site Number : 8400077
    Little Rock, Arkansas 72205, United States
  • Charles R. Drew University of Medicine and Science Site Number : 8400220
    Los Angeles, California 90059, United States
  • Peninsula Research Associates, Inc. Site Number : 8400094
    Rolling Hills Estates, California 90274, United States
  • Optimal Research Site Number : 8400173
    San Diego, California 92108, United States
  • Yale University Site Number : 8400239
    New Haven, Connecticut 06510, United States
  • The George Washington University Site Number : 8400212
    Washington D.C., District of Columbia 20037, United States
  • Cenexel Research Centers of America Site Number : 8400089
    Hollywood, Florida 33024, United States
  • Optimal Research, LLC Site Number : 8400057
    Melbourne, Florida 32934, United States
  • Synexus Clinical Research US, Inc. - Orlando Site Number : 8400179
    Orlando, Florida 32806, United States
  • Emory University Decatur Site Number : 8400201
    Decatur, Georgia 30030, United States
  • Chicago Clinical Research Institute, Inc. Site Number : 8400269
    Chicago, Illinois 60607, United States
  • Optimal Research Site Number : 8400187
    Peoria, Illinois 61614, United States
  • Synexus Clinical Research Evansville Site Number : 8400272
    Evansville, Indiana 47714, United States
  • Research Works INC Site Number : 8400045
    New Orleans, Louisiana 70125, United States
  • Optimal Research, LLC Rockville Site Number : 8400048
    Rockville, Maryland 20850, United States
  • Brigham and Women's Hospital Site Number : 8400199
    Boston, Massachusetts 02115, United States
  • Synexus St. Louis Site Number : 8400100
    St Louis, Missouri 63141, United States
  • Velocity Clinical Research, Omaha Site Number : 8400030
    Omaha, Nebraska 68134, United States
  • Holy Name Medical Center Site Number : 8400072
    Teaneck, New Jersey 07666, United States
  • NYU VC-Augustana Site Number : 8400267
    Brooklyn, New York 11220, United States
  • New York University Langone Vaccine Center Site Number : 8400230
    New York, New York 10016, United States
  • Columbia University Irving Medical Center Site Number : 8400203
    New York, New York 10032, United States
  • University of Rochester Site Number : 8400207
    Rochester, New York 14642, United States
  • University of Pittsburgh Site Number : 8400233
    Pittsburgh, Pennsylvania 15213, United States
  • Coastal Carolina Research Center Site Number : 8400097
    North Charleston, South Carolina 29405, United States
  • American Indian Clinical Trials Research Network Site Number : 8400204
    Rapid City, South Dakota 57701, United States
  • AES Austin Site Number : 8400191
    Austin, Texas 78744, United States
  • Investigational Site Number : 0360001
    South Brisbane, Queensland 4101, Australia
  • Investigational Site Number : 0360003
    Norwood, 5067, Australia
  • Investigational Site Number : 0360002
    Southport, 4215, Australia
  • Investigational Site Number : 0360005
    Westmead, 2145, Australia
  • Investigational Site Number : 0360004
    Woodville, 5011, Australia
  • Investigational Site Number : 2500013
    Dijon, 21079, France
  • Investigational Site Number : 2500008
    Limoges, 87042, France
  • Investigational Site Number : 2500014
    Lyon, 69004, France
  • Investigational Site Number : 2500015
    Marseille, 13005, France
  • Investigational Site Number : 2500016
    Marseille, 13005, France
  • Investigational Site Number : 2500006
    Nantes, 44093, France
  • Investigational Site Number : 2500005
    Paris, 75679, France
  • Investigational Site Number : 2500003
    Pessac, 33600, France
  • Investigational Site Number : 2500007
    Pierre-Bénite, 69495, France
  • Investigational Site Number : 2500004
    Rennes, 35033, France
  • Investigational Site Number : 2500002
    Tours, 37044, France
  • Investigational Site Number : 3400002
    Municipio Del Distrito Central, 11101, Honduras
  • Investigational Site Number : 3400001
    San Pedro Sula, 21104, Honduras
  • Investigational Site Number : 5540005
    New Lynn, Auckland 0600, New Zealand
  • Investigational Site Number : 5540002
    Christchurch, 8013, New Zealand
  • Investigational Site Number : 5540007
    Nawton, 3243, New Zealand
  • Investigational Site Number : 5540010
    Nelson, 7011, New Zealand
  • Investigational Site Number : 5540001
    Rotorua, 3010, New Zealand
  • Investigational Site Number : 7240013
    Santiago de Compostela, Galicia [Galicia] 15706, Spain
  • Investigational Site Number : 7240016
    Majadahonda, Madrid 28222, Spain
  • Investigational Site Number : 7240009
    Madrid, 28041, Spain
  • Investigational Site Number : 7240008
    Valencia, 46020, Spain
  • Investigational Site Number : 7240003
    Vigo, 36312, Spain
  • Investigational Site Number : 8260011
    Runcorn, Halton WA7 2DA, United Kingdom
  • Investigational Site Number : 8260017
    Bath, Somerset BA1 3NG, United Kingdom
  • Investigational Site Number : 8260013
    Surrey, Sutton SM2 5PT, United Kingdom
  • Investigational Site Number : 8260014
    Doncaster, DN4 8QN, United Kingdom
  • Investigational Site Number : 8260016
    Gloucester, GL1 3NN, United Kingdom
  • Investigational Site Number : 8260010
    Harrow, HA1 3UJ, United Kingdom
  • Investigational Site Number : 8260015
    London, SW10 0LR, United Kingdom
  • Investigational Site Number : 8260012
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. PubMed 37533419 ↗
  • Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect Dis. 2022 May;22(5):636-648. doi: 10.1016/S1473-3099(21)00764-7. Epub 2022 Jan 25. PubMed 35090638 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jun 2023, 28 months.

Results were first posted in Sep 2025, 2 years 2 months after primary completion. A results delay was requested in Jun 2024.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 28 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 21, 2021
StartActual
Feb 24, 2021
Primary completionActual
Jun 29, 2023
CompletionActual
Jun 29, 2023
Results delay requested
Jun 24, 2024
Results first posted
Sep 18, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04762680
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Feb 24, 2021
Primary completion
Jun 29, 2023
Completion
Jun 29, 2023
Results posted
Sep 18, 2025
Last update
Sep 18, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion